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Abstract
Purpose This study aims to explore how long-term drug
users with a Pakistani background living in Oslo (Norway)
perceive generic substitution and how generic substitution
influences drug adherence in this population.
Methods Personal interviews using a semi-structured ques-
tionnaire were carried out with 83 Pakistani immigrants
(aged 40–80 years) who were using antihypertensives,
antidiabetics, and/or cholesterol-lowering drugs.
Results In all, 73% of the participants were using generic
drugs at the time of the interview. Of these, 10% were
erroneously using two equivalent generics at the same time.
One quarter of the participants were of the opinion that
cheaper generic drugs were counterfeit drugs. Two thirds
had accepted generic substitution in the pharmacy whereas
the remaining participants had either opposed or were
unaware of the substitution. Of those who had accepted
substitution, 27% claimed that the effect of the new drug
was poorer and 20% reported more side-effects. Generic
substitution had resulted in concerns about the therapy in
41% of the patients, and 26% thought it had become more
demanding to keep track of their medication. Poor
adherence tended to be most common among patients
who were not fluent in Norwegian, patients who had
concerns about medicine use, and patients who had
accepted generic substitution in the pharmacy.
Conclusion This study shows that generic substitution may
have a negative effect on drug adherence in Pakistani
immigrants in Oslo (Norway) because of concerns and
misconceptions, including confusion with regard to coun-
terfeit drugs. Problems result primarily from inadequate
information caused by language barriers but also from
culturally conditioned views on encounters with the health
care system.
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Introduction
Due to their low cost profile, there is a strong global focus
on generic drugs. Increased use of these drugs has been
promoted by governments as a means of combatting the
growth in the public pharmaceutical budget, and most
Western countries have implemented generic prescribing
and/or generic substitution in order to achieve this [1–6]. In
low-income countries, the availability of cheaper generics is
pivotal to access to affordable medication for many patients
[7]. It is estimated that these drugs account for the largest
shares of total sales in the poorest parts of the world [8].
Since the late 1960s immigration from Pakistan to
Norway has been considerable. Currently, Pakistani immi-
grants constitute the largest foreign ethnicity group in the
capital city, Oslo [9]. There are large contrasts between the
two countries. Norway has a comprehensive reimbursement
scheme that provides the inhabitants with quality-assured
pharmaceuticals. The patients have to cover a 38% copay-
ment, restricted upwards to €230 a year. In all, 70% of
pharmaceutical expenditure is reimbursed by the govern-
ment [10]. In Pakistan, on the other hand, more than the
same amount is out-of-pocket expenses [8]. Whereas the
Norwegian pharmaceutical market is subject to strict
control, Pakistan governments struggle with unresolved
regulatory issues with respect to pharmaceutical quality
[11]. However, the governments of both countries are
strong advocates of generic drug use.
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has been allowed since 2001 [3]. This implies that the
pharmacies are obliged to stock less expensive generics and
offer them to the patients unless the price difference is
insignificant. As for the approval and the distribution of
drugs in general, the generic market segment is strictly
regulated both clinically (involving bioequivalence testing
and ongoing reporting of adverse events [12, 13]) and
economically. Regarding the economical issues, strong
incentives in favour of choosing the less expensive generic
versions (usually the non-branded drugs) have been imple-
mented. Itimplies bothhighermarginsfor the pharmaciesand
avoidance of extra payments for the patients [3]. In this way,
the Norwegian market of cheaper generics has developed
substantially such that by 2009 as much as 70% of the
defined daily doses in the generic interchangeable market
were sold as cheaper generic versions [10].
In Pakistan, cheaper generic brands are available in the
pharmacies and sold on average at half the price of their
brand-name equivalents [7]. Ideally, these products should
make it possible for the parts of the population who would
otherwise be without treatment to receive affordable drugs.
However, despite the lower prices, the patients as well as
the health care providers are reluctant to use these drugs
[11, 14, 15]. This may be due to the fact that generic
manufacturers are not required to provide bioequivalence
data and that there is a significant market for counterfeit
products in the country [16, 17].
Despite the high number of Pakistani immigrants in
Norway and the relatively long time that many of them
have been residing in the country, studies of drug use in this
population have not been identified. The research on
generic substitution from Norway is restricted to the general
population [18–20] (with about 10% immigrants) and
health professionals [21]. Despite the different scenarios
regarding quality and safety measures between the countries,
studies have demonstrated that Norwegian patients are also
uneasy about generic substitution [18–21], and that it may
influence drug adherence intentionally as well as uninten-
tionally [18]. Moreover, several studies have shown that in
order for generic substitution to be successful with regard to
safe medicine use, information is a key factor [18, 22, 23].
This may be even more important among immigrants since
they may in addition experience language barriers. It is not
inconceivable that the accessibility of necessary information
related to, for instance, drug use becomes more restricted.
Furthermore, past experiences from their home country may
elicit concerns about the quality of cheaper drugs, despite the
new setting being a well-regulated health care system.
The aim of the present study was to explore how Pakistani
immigrants on long-term drug treatment who live in Norway
perceive generic substitution and to investigate how generic
substitution influences drug adherence in this population.
Materials and methods
Study population
The study population consisted of 83 first-generation
Pakistani immigrants living in Oslo, the capital city of
Norway, or the surrounding area. The participants had to
be chronic drug users on long-term therapy with antihy-
pertensives, antidiabetics, and/or cholesterol-lowering
drugs, and be in the age group 40–80 years, since non-
adherence is a well-known problem in this kind of patients
[24].
Recruitment
The participants were recruited opportunistically in collab-
oration with two voluntary special interest groups (The
International Health and Social Group and The Pakistani
Woman Group), which work on strategies to improve
integration of ethnic minorities. Information was provided
during the networks’ organised meetings for elderly
immigrants (where the participants were mainly Pakistani)
or at cafes where they gathered. In addition, other network
members who fulfilled the inclusion criteria but were not
present at any meetings were contacted by telephone by the
network leaders.
All potential participants were given oral and/or
written standardised information about the study in
Norwegian and/or Urdu before they were asked to take
part in the study. Those who were interested in taking
part were put in contact with the interviewer and the time
and setting for the interview was arranged. The response
rate was 69%.
Study design
The study design was explorative and based on personal
face-to-face interviews using a semi-structured question-
naire. The questionnaire was originally developed for a
previous Norwegian study that explored drug adherence
following generic substitution in the general Norwegian
population [18]. Based on experience with the question-
naire from the previous study, the questionnaire was
modified in order to fit the target population, i.e. some
questions were added (e.g. experiences from Pakistan with
counterfeit drugs and drugs in general), more closed
questions were followed by open-ended questions (i.e. to
be more explorative), and more response options were
added to some of the closed questions. Three quarters of the
questions were open-ended or were followed by open-
ended follow-up questions. Eleven questions dealt with
drug adherence and attitudes towards drug use in general,
including an estimation of how many doses they had
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last 14 days and whether or not they took drug holidays or
in any other way used the drugs in ways other than the
physician prescribed. Also, as part of the interview, all the
participants had to tell and show which drugs they used at
the time of the interview. Attitudes towards generic
substitution constituted 17 questions and dealt with how
the patients felt about substituting their drug(s) and their
experiences with substitution. The patients were also asked
to value the brand-name drugs compared with the generic
alternatives in a simple willingness-to-pay exercise in order
to unravel their attitudes towards generics from a different
angle. The questionnaire was piloted before starting the
study.
Each of the participants gave their informed consent
(provided in Norwegian and Urdu) in writing. The study
was approved by the Regional Committee for Medical and
Health Research Ethics and the Norwegian Social Science
Data Services.
Data collection
One interviewer conducted all the interviews during the
period from October 2009 to February 2010, preferably in
the informants’ home. The interviews were conducted with
an Urdu/Punjabi translator if this was found necessary from
the pre-interview contact with the patient or his/her
relatives.
Data analysis
The software SPSS (version 16.0) was used in the
preparation of the data. The analyses were strictly descrip-
tive. The answers to open-ended questions were coded and
analysed categorically.
For all participants, a scale score of drug adherence was
constructed by giving values to possible combinations of
answers to the adherence questions (1=often forgets and
deliberately alters the recommended dose and takes/has
taken multiple dosing of the same active ingredient, to
5=never forgets nor deliberately alters the recommended
dose nor takes/has never taken multiple dosing of the same
active ingredient). Based on these scores the participants
were categorised as having poor (lower part of the scale) or
good (upper part of the scale) adherence.
Results
Characteristics of the study population
The 83 long-term drug users who participated in the study
had an average age of 57.8 years (range: 43–77) and their
mean length of residence in Norway was 29.3 years (range:
3–41). Eighty percent of the participants had some
education, of whom 20% had higher education (> 12 years).
Fifteen percent of the patients were actively employed.
Sixty-five percent of the interviews were conducted with an
Urdu or Punjabi translator since the participants were not
fluent in Norwegian.
The participantshad onaverage 3.4 diagnoses (range: 1–9)
for which they were treated with drugs. In all, 76%, 67%,
and 51% used antihypertensives, antidiabetics, and/or
cholesterol-lowering drugs respectively. The mean number
of total prescription drugs was 6.7 (range: 1–28). Fifty
percent of the participants claimed that they knew why it
was advisable to treat their chronic condition(s) medically.
Forty-seven percent reported that they had general concerns
regarding medicine use, and 53% were apprehensive about
side-effects in particular. Further details of the study
population—in relation to whether or not they had ever
accepted generic substitution—are shown in Table 1.
Patients’ perceptions of and experiences with generic
substitution
Two thirds of the participants had always or sometimes
accepted generic substitution in the pharmacy. Twenty-two
percent said that they never accepted substitution, of whom
nearly half had had their drugs substituted anyway without
being aware of it. The remaining participants were
unfamiliar with the problem as presented. In total, 73% of
the participants were using non-branded drugs at the time of
the interview. According to Table 1, generic substitution
tended to be relatively more accepted in the younger age
groups, among those with higher education, and among
those who were sufficiently informed about both generic
substitution and the drug therapy they were on. Language
barriers and concerns about the drug therapy and particu-
larly side-effects were relatively more prevalent among
those who had accepted the substitution. The willingness to
accept substitution increased with higher education. The
reasons given for not accepting generic substitution are
presented in Table 2.
One quarter of the participants were of the opinion that
cheaper generic drugs were fake drugs. They used the term
“no. 1” for brand-name drugs whereas “no. 2” alluded to
counterfeit and non-branded drugs. In some cases different
non-branded products were categorised as “no. 1” and “no.
2” according to the order in which they were purchased. All
of the participants were aware of the situation with
counterfeit drugs in Pakistan as they had been informed
by friends or the media, and 8% had experienced using
these drugs in Pakistan themselves.
Of those who had accepted generic substitution, 41%
were concerned when they started using the generically
Eur J Clin Pharmacol (2011) 67:193–201 195Patients who accepted
generic substitution
Patients who refused
generic substitution
n % n %
Sociodemographic characteristic
Gender
Female 30 58.8 21 41.2
Male 24 75.0 8 25.0
Age (years)
40–49 11 68.8 5 31.2
50–59 23 67.6 11 32.4
60–69 16 64.0 9 36.0
70–79 4 50.0 4 50.0
Educational level
None 7 41.2 10 58.8
Primary or secondary (≤12 years) 35 66.0 18 34.0
Tertiary (> 12 years) 12 92.3 1 7.7
Length of residence in Norway (years)
<10 0 0 1 100
10–19 6 75.0 2 25.0
20–29 13 54.2 11 45.8
≥30 35 70.0 15 30.0
Fluent Norwegian speaker
Yes 28 51.9 26 48.1
No 26 89.7 3 10.3
Medical characteristic
Antihypertensive drug use
Yes 44 69.8 19 30.2
No 10 50.0 10 50.0
Antidiabetic drug use
Yes 36 64.3 20 35.7
No 18 66.7 9 33.3
Cholesterol-lowering drug use
Yes 30 71.4 12 28.6
No 24 58.8 17 41.5
Knowledge of the aim of the drug therapy
Yes 32 76.2 10 23.8
No 22 53.7 19 46.3
General concerns about medicine use
Yes 29 74.4 10 25.6
No 25 56.8 19 43.2
Concerns about side-effects
Yes 34 82.9 7 17.1
No 20 47.6 22 52.4
Received sufficient information
about generic substitution
a
Yes 29 85.3 5 14.7
No 15 40.0 10 60.0
Table 1 Characteristics of the
study population with respect to
their generic substitution status
(dichotomised as having ever or
having never accepted
substitution; n=83)
an=59
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the effect of the drug had changed, and all of these had
experienced a poorer and/or slower effect (e.g. quote: “the
no. 1s work 100%; the no. 2s work 70%”). Twenty percent
reported having experienced new or more side-effects. Of
all the participants, 12% had a physician’s exemption from
generic substitution on the prescription because of a
negative experience with the alternative product.
Table 3 shows that 46% of the participants were willing
to pay something extra in addition to the basic copayment
to avoid generic substitution. These participants were
primarily those who reported a change in effect and/or
those who had experience with fake medicines from
Pakistan and were afraid the same could happen in Norway.
Adherence to medical treatment
A total of 46% of the participants thought it was difficult to
remember to take their medication every day. During the
previous 2 weeks, 31% said they had forgotten to take some
of their medications about once a week while 11% said they
forgot several times per week or even daily. Thirty-one
percent reported that they had deliberately abstained from
taking their medications from time to time, and 16%
admitted that this had happened during the previous
2 weeks. Eighteen percent told that they occasionally took
drug holidays. The main reasons for their intentional non-
adherence were: side-effects, feeling healthy, travelling,
running out of medication, and being dispensed non-
branded generics in the pharmacy. Of those who had had
their drug(s) substituted in the pharmacy, 26% found it
more demanding to keep track of their medication after the
switch since they no longer knew their medication by name
or appearance. It became difficult to recognise the drugs
and know which drugs the new ones were replacing or for
which purpose they were to be used. This was an extra
challenge for those who were not literate or had poor
eyesight. Fifty percent had noticed that the non-branded
product had a different shape, size, or colour compared with
the brand-name product they had received previously. Some
commented on the convenience of a blister package over a
box container since they were easier to carry with them and
also more hygienic to use.
Trends in the results presented in Table 4 indicate that
poor adherence was relatively more common among
patients who were not fluent in Norwegian, among those
who were generally concerned about medicine use and
particularly side-effects, and among those who had accept-
ed generic substitution in the pharmacy. Ten percent of the
participants who were using generics were using two
different products containing the same active ingredient,
i.e. a branded and a non-branded drug, at the same time.
These patients used several different drugs (3–13 drugs)
and were, independently, patients who retrieved their
medications from more than one pharmacy. At the same
time they were among those who were unable to commu-
nicate with the pharmacy personnel either because they did
not speak Norwegian or because they did not go to the
pharmacy themselves. Some of them were not aware of
the substitution in the first place and/or felt strongly against
it.
Table 2 Examples of the patients’ reasons for refusing generic
substitution (n=50; multiple responses)
Reason for refusing generic substitution Number of
responses (%)
Suspected the non-branded drugs of being fake
medications
12 (19.7)
“No. 1”/brand-name medication is the best 10 (14.8)
Used to the “no. 1”/brand-name drug 9 (14.8)
The physician should decide (since he/she knows
my body best)
9 (14.8)
Uncertain about the substitution in general 8 (13.1)
Fear/experience of side-effects 4 (6.6)
Cheaper medication is of poorer quality 3 (4.9)
Fear/experience of poorer effect 3 (4.9)
Felt better about the brand-name drug 2 (3.3)
Warning from family and friends 1 (1.6)
Distrust in drugs produced outside Norway 1 (1.6)
The patients’ consideration of the copayment
b
Inexpensive Expensive Don’t know Total
Extra payment (in Euros
a) 0 12 11 2 25
0.1–6.5 6 4 0 10
6.5–26 5 7 2 14
26–65 1 1 0 2
More than 65 3 8 1 12
Don’t know 4 12 4 20
Total 31 43 9 83
Table 3 The amount the
patients were willing to pay
extra for the brand-name drug in
relation to how they considered
the copayment
aConverted from Norwegian
kroner
b38% of the retail price;
maximum €230 a year
Eur J Clin Pharmacol (2011) 67:193–201 197Information and knowledge about generic substitution
Generic substitution was known to 82% of the participants
in the study. All of these had received some information
about the substitution in the pharmacy except those who did
not visit the pharmacy themselves and were informed to
some degree by family members and/or friends. They had
been told briefly that the drug they were being dispensed
was a cheaper but equivalent version of the brand-name
drug, which was produced by another firm. In addition,
43% had received some kind of information from their
physician. Of the remaining, many expressed that they
Poor adherence Good adherence
n % n %
Sociodemographic characteristic
Gender
Female 10 19.6 41 80.4
Male 6 18.8 26 81.2
Age (years)
40–49 3 18.8 13 81.2
50–59 9 26.5 25 73.5
60–69 3 12.0 22 88.0
70–79 1 12.5 7 87.5
Educational level
None 2 11.8 15 88.2
Primary or secondary (≤12 years) 12 22.6 41 77.4
Tertiary (> 12 years) 2 15.4 11 84.6
Length of residence in Norway (years)
<10 0 0 1 100
10–19 1 12.5 7 87.5
20–29 4 16.7 20 83.3
≥30 11 22.0 39 78.0
Fluent Norwegian speaker
Yes 7 13.0 47 87.0
No 9 31.0 20 69.0
Medical characteristics
Number of prescription drugs
≤ 7 (average value or less) 11 18.6 48 81.4
> 7 (more than average value) 5 20.8 19 79.2
Knowledge of the aim of the drug therapy
Yes 7 16.7 35 83.3
No 9 22.0 32 78.0
General concerns about medicine use
Yes 11 28.2 28 71.8
No 5 11.4 39 88.6
Concerns about side-effects
Yes 12 29.3 29 70.7
No 4 9.5 38 90.5
Received sufficient information
about generic substitution
a
Yes 11 32.4 23 67.6
No 5 20.0 20 80.0
Accepted generic substitution in the pharmacy
Yes 15 27.8 39 72.2
No 1 3.4 28 96.6
Table 4 Distribution of
adherence outcome in relation to
possible explanatory variables
(n=83)
an=59
198 Eur J Clin Pharmacol (2011) 67:193–201would have felt more positive and safe about generic
substitution if their physician had given some information
about the substitution or prescribed the version they
obtained in the pharmacy. About half of those who reported
having received information considered it to be sufficient
for being able to feel safe about using the drug(s). The
patients’ perception of why the pharmacy personnel asked
them to substitute their medicine(s) in the pharmacy are
shown in Fig. 1.
Discussion
The present study explores how generic substitution is
perceived by a population of Pakistani immigrants in Oslo,
Norway. It is the second Norwegian study to show that
generic substitution can be an additional challenge for drug
adherence in patients on long-term therapies [18]. Both
studies show that adherence may be affected intentionally
as well as unintentionally because of concern and confusion
regarding the new product. However, these results are most
pronounced in the present study. Whereas 5% of the general
population group unintentionally used more than one
equivalent generic drug at the same time [18], the
percentage among the Pakistani immigrants was twice as
high. Furthermore, a considerably larger proportion of the
Pakistani patients claimed that they had experienced a
change in the effect or new or more side-effects. This
mirrors the fact that they were also generally more
concerned about substitution. Both studies show that the
chance of erroneous drug use seems to increase for patients
who are using more than one pharmacy for their drug
purchases and for patients who are, for various reasons, not
well informed about the intervention. In the present study,
the patients who were erroneously using two equivalent
generics at the same time were unable to communicate with
the pharmacy personnel.
Insufficient information also tends to be a reason for
having a negative attitude towards generic drugs. There was
a clear association between non-branded generics and
counterfeit products among the participants. Those who
were unwilling to substitute their drugs generically rea-
soned that something that was cheaper could not have the
same quality as more expensive products. A considerable
proportion of the participants in this study perceived non-
branded drugs, often referred to as “no. 2s”, as counterfeit
drugs. A negative attitude towards generic substitution was
reflected in the willingness to pay extra to avoid substitu-
tion even if they thought they had already paid enough in
copayments. The patients’ perception of high copayments
may be explained by expectations of free services in a
health care system based on high tax financing, of which
the Norwegian one is an example [25]. Regarding patients
experiencing language problems, it may seem a paradox
that these patients were more prone to accept generic
substitution; however, this may simply be because when
asked about substitution in the pharmacy they responded
without having understood or because they did not manage
to articulate any response.
The participants in this study were recruited from the
capital city of Norway since this is the region where by far
the most Pakistani immigrants have settled [9]. The age
range 40–80 years was selected in order to encompass a
wide group of drug users with experience of how to cope
with chronic conditions and, for many, multiple medica-
tions. The selected conditions (i.e. hypertension, diabetes,
and hypercholesterolaemia), which are of high prevalence
regardless of ethnicity, often carry with them the necessity
for life-long drug therapy. Moreover, the drugs used to treat
these conditions are primarily off-patent, and it is likely that
most patients have been offered a cheaper generic alterna-
tive in the pharmacy. Regarding the representativity of the
present study, it must be taken into account that the number
of participants is relatively small. However, even this
modest number of participants could only be recruited by
involving special interest or network groups. It would have
been by no means possible to have achieved a satisfying
result without the help obtained from leading persons in
Fig. 1 The relationship between
the number of patients and these
patients’ reasons for why the
pharmacy personnel asked them
to substitute their medicine(s)
for generic ones (n=83; multiple
responses)
Eur J Clin Pharmacol (2011) 67:193–201 199Norway’s Pakistani population. The fact that these people
vouched for the reliability of the study conductors was key
in the recruitment process, particularly as subjects had to
allow the interviewer to take a look at their medication. For
convenience therefore, the interviews were conducted in the
participants’ homes wherever possible.
The results from this study are not consistent with those
from Dutch researchers van Wijk et al. [26]. Based on data
from a prescription database, van Wijk et al. concluded that
generic substitution of antihypertensive drugs did not result
in lower adherence or more cardiovascular disease-related
hospitalisations [26]. In both countries the pharmacy
personnel are supposed to provide guidance in appropriate
drug use; however, since Dutch patients usually register at a
single pharmacy, it is conceivably easier to avoid erroneous
drug use related to generic substitution. The different results
may also be at least partially explained by the use of different
methods. The present study made it feasible to discover
problemsthatoccurred on a personallevel.These findingsare
not reflected in larger population-based datasets.
Patients may become insecure when questions about
generic substitution are posed by the pharmacy personnel.
As explored by for instance Waber et al. there is a
significant association between reported effect and price
regarding pharmaceutical products [27]. However, many
patients accept non-branded generics if they had been
approved or prescribed by their doctor [18, 28, 29]. In the
case of first-generation immigrants, symmetric informa-
tion from the different kinds of health professionals tends
to be extremely important. The present study clearly
demonstrates the importance of patient education, espe-
cially with regard to immigrants who may experience
language as well as cultural barriers. Despite the moderate
sample, it was possible to observe distinct differences in
how generic substitution is perceived among Pakistani
immigrants compared with the general Norwegian popu-
lation [18].
Conclusion
This exploratory study shows that generic substitution may
have a negative effect on drug adherence in Pakistani
immigrants with chronic conditions living in Oslo (Norway).
Concerns about the equality of the interchangeable drugs,
experiences of change in effect or more side-effects, and
confusion regarding counterfeit drugs made many patients
apprehensive about using the cheaper generic alternatives.
Also, because of confusion after substitution, 1 in 10 patients
were simultaneously using two equivalent generics. These
problems result primarily from inadequate knowledge caused
by language barriers, but also from culturally conditioned
views on encounters with the health care system.
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